Previous 10 | Next 10 |
home / stock / chgcy / chgcy news
Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. The current low-quality rally offers an opportunity to look back on the lessons from the last time the markets coo...
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2021 Earnings Conference Call April 22, 2021 05:00 AM ET Company Participants Osamu Okuda - President & Chief Executive Officer Toshiaki Itagaki - Executive Vice President & Chief Financial Officer Tetsuya Yamaguchi - Senior Vice President, H...
The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2021 Q1 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2021 Q1 - Results - Earnings Call Presentation
Chugai Pharmaceutical experienced unexpected demand for the drug Actemra during the pandemic, but sales appear to have peaked in FY12/2020. New releases such as Hemlibra should begin to scale in FY12/2021, together with distribution sales of Roche's Tecentriq. The company has a st...
A Phase 1 trial has demonstrated that a new coronavirus treatment helped patients with moderate-to-serious COVID-19 to recover within days, Tel Aviv’s Ichilov Medical Center said on Friday, according to The Times of Israel.Out of 30 patients with moderate or severe COVID-19, ...
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q4 2020 Earnings Conference Call February 04, 2021 04:00 AM ET Company Participants Tatsuro Kosaka - Chairman & Chief Executive Officer Toshiaki Itagaki - Executive Vice President & Chief Financial Officer Tomoyuki Igawa - Chief Executive Office...
The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2020 Q4 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2020 Q4 - Results - Earnings Call Presentation
Shares of Chugai Pharmaceutical (CHGCY) surged 6% in Japan after the U.K. government found that company's rheumatoid arthritis drug, tocilizumab was effective in reducing risk of death as well as hospitalization time for COVID-19 patients, CNBC reports.In a press release dated Thurs...
Chugai Pharma Taiwan, a wholly-owned subsidiary of Chugai Pharmaceutical (CHGCY) has obtained an import drug license approval from the Taiwan Food and Drug Administration ((TFDA)) for it’s Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for...
Chugai Pharmaceutical Co Ltd (CHGCF) Q3 2020 Earnings Conference Call October 22, 2020, 05:00 ET Company Participants Toshiaki Itagaki - CFO Minoru Hirose - Department Manager, R&D Portfolio Management Dept. Shinji Hidaka - VP & Head, Marketing & Sales Division Conference Call Par...
News, Short Squeeze, Breakout and More Instantly...
Chugai Pharmaceuticals Co. Ltd. ADR Company Name:
CHGCY Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
Grandsouth Bancorporation (GRRB) is expected to report for quarter end 2023-09-30 Cadence Bank (CADE) is expected to report $0.56 for Q3 2023 Enterprise Financial Services Corporation (EFSC) is expected to report $1.24 for Q3 2023 Blackhawk Bancorp Inc. (BHWB) is expected to report fo...